Strikingly, transforming growth factor alpha (TGFα) was uniquely elevated in the CML patients that failed EMR and was a more significant predictor of failed response to imatinib treatment than IL-6. The gene discussed is TGFA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.